Abstract Library

#4383 Clinical and biological heterogeneity of grade 2 gastroenteropancreatic neuroendocrine neoplasms (GEP NENs): Prognostic significance of the 10% Ki-67 index cutoff and implications for treatment strategies

Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEP NENs) are a diverse group of neoplasms with varying prognoses. Grade 2 (G2) tumours, with a Ki-67 index between 3%-20%, present management challenges due to their intermediate behaviour, with evidence suggesting distinct outcomes between Ki-67

Conference:

Presenting Author: Massironi S

Authors: Massironi S, Coltro L, Gallo C, Preatoni P, Dell' Anna G,

Keywords: Neuroendocrine neoplasm, Ki-67 Index, Grade 2 Neuroendocrine Tumour, Neoplasm Grading, Tumour Heterogeneity, Progression-Free Survival (PFS), Peptide Receptor Radionuclide Therapy,

#4176 A single center experience of locoregional treatments application in neuroendocrine liver metastases

Introduction: Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) are complicate with neuroendocrine hepatic metastasis (NELM) in approximately 60% of cases. Loco-regional interventional radiology procedures are widely approved in treatment of hepatocellular carcinoma (HCC) and in last years found more and more application in liver metastasis.

Conference:

Presenting Author: Ferretti S

Authors: Masoni B, Ferretti S, Rossi R, Ceriani R, Laffi A,

Keywords: neuroendocrine, loco regional treatment, liver metastasis, interventional radiology, embolization, ablation,

#4160 Pancreatic neuroendocrine tumors mimicking pancreatic metastases from renal neoplasms

Introduction: The CT-finding of a hypervascular pancreatic lesion in patients with past nephrectomy for renal clear cell cancer (RCC) or synchronous renal neoplasm is suspected for pancreatic metastasis from RCC.

Conference:

Presenting Author: Milanetto A

Authors: Pasquali C, Armellin C, Milanetto A,

Keywords: renal clear cell cancer, pancretic NET,

#3885 Adaptive immunosuppressive resistance mechanisms towards antiangiogenic immunotherapies revealed in a pancreatic neuroendocrine tumor (PNET) model

Introduction: Pancreatic neuroendocrine tumors (PNETs) are mostly indolent but can achieve malignancy. Surgery is the only approved first-line therapy. Kinase inhibitors and radiotherapy for unresectable PNETs are non-curative and targeted therapies are currently lacking for PNETs. However, immune checkpoint inhibitors have created a paradigm shift in cancer therapy with significant increase in overall survival, but are curative only in a subset of patients, partly due to limited T cell infiltration, especially in angiogenic and cold tumors like PNETs. Parallelly, antiangiogenic therapy increases lymphocyte infiltration by normalising the tumor vasculature. Tallying antiangiogenic to immunotherapies (AI) has provided improved survival benefits for patients of advanced RCCs and HCCs, while other cancers like glioblastoma remain highly resistant.

Conference:

Presenting Author:

Authors: John Robbert D, Guyot M, Killian T, Verslype C, Lambrechts D,

Keywords: Pancreatic neuroendocrine tumor, Antiangiogenic immunotherapy, single cell transcriptomics, Immunosuppression,

#3880 Neoadjuvant peptide receptor radionuclide therapy (PRRT) with 90-Yttrium versus 177-Lutetium – Comparison of clinico-pathological and survival outcomes

Introduction: The role of peptide receptor radionuclide therapy (PRRT) as neoadjuvant treatment in patients with is still controversial, although recent experiences showed encouraging results in terms of oncological outcomes.

Conference:

Presenting Author: Genova L

Authors: Genova L, Andreasi V, Partelli S, Muffatti F, Battistella A,

Keywords: peptide receptor radionuclide therapy, prrt, neoadjuvant, surgery, yttrium, lutetium,